ArticleLipids in health and disease2019
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.
Article in Lipids in health and disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Bempedoic Acid can Reduce Cardiovascular Events in Combination with Statins or As Monotherapy: A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023 · on this mapPooled it
- Pooled it
- Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.American heart journal · 2026Trial
- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.Journal of the American College of Cardiology · 2021Trial
- Changes in statin therapy following discharge in those with cardiovascular disease in Ireland.Irish journal of medical science · 2026Article
- Treatment Patterns and Healthcare-Related Costs in Patients with Atherosclerotic Cardiovascular Disease: Insights from a Large US Healthcare Insurer.Drugs - real world outcomes · 2026Article
- Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.Translational and clinical pharmacology · 2026Article
- Machine Learning Prediction Model for Dyslipidemia and Its Association With Atherothrombotic Events in 3 Independent Cohorts From South Korea, Japan, and the United Kingdom: Algorithm Development and Validation Study.JMIR medical informatics · 2026Article
- Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study.Lipids in health and disease · 2026Observational
- Pharmacogenetic Associations with Statin Regimen Modification, Intolerance, and Adverse Outcomes in Coronary Artery Disease Patients.Pharmaceuticals (Basel, Switzerland) · 2026Article
- LDL-C lowering in patients treated with bempedoic acid in a real-world cohort.Atherosclerosis plus · 2026Article
- Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease.Gene therapy · 2026Review
- Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Treatment pathways of lipid-lowering therapies in Germany 2016-2022.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease.Journal of the Saudi Heart Association · 2026Article
- Short- and Long-Term Statin Persistence and Determinants in Patients Initiating Statin Therapy.Medeniyet medical journal · 2025Article
- Are statin side effects dependent on sex? A narrative review.Przeglad menopauzalny = Menopause review · 2025Review
- Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.International journal of molecular sciences · 2025Review
- Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy.Drugs · 2025Review
- Role of Bailout Gene-Silencing Therapy in Plaque Lipid Reduction: Intravascular Imaging Study.Cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundA decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured long-term statin persistence in patients with high CV risk.
methodsThis retrospective administrative claims analysis of the Optum Research Database included patients aged ≥ 45 years with diabetes and/or atherosclerotic CV disease (ASCVD) who had a statin prescription filled in 2010. It included an elevated triglycerides (TG) cohort of patients with index date in 2010 and TG ≥ 150 mg/dL (n = 23,181) and a propensity-matched comparator cohort with TG < 150 mg/dL and high-density lipoprotein cholesterol > 40 mg/dL (n = 23,181). Both cohorts were followed for ≥ 6 months up to March 2016.
resultsThe probability of remaining on a prescription fill for index statin therapy was 47% after 1 year and 19% after 5 years in both cohorts. Statin persistence was worse among women than men, and among younger versus older patients (P < 0.001 for all comparisons). After 5 years, the probability of remaining on a prescription fill for index statin was < 25% across all subgroups assessed including patients with and without baseline revascularization, heart failure, peripheral artery disease and renal disease. Similar results were observed in a subcohort analysis of patients with TG 200-499 mg/dL.
conclusionsLong-term statin persistence after 5 years is alarmingly low (< 25%) and is a public health concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.